HER 2, estrogen receptor and progesterone receptor (PR) expression in patients with advanced stage breast cancer has been investigated by Vignot et al (23); marked discrepancies were found for PR expression, however, no definitive conclusions could be drawn, particularly with regard to the clinical impact of such findings. The gene discussed is ESR1; the disease is breast carcinoma.